₹6,797
▼ -57.58 -0.84%
17 Jul 2026
NSE Listed
Procter & Gamble Health Limited (PGHL)
20-day avg volume: 24K shares
- Healthy return on equity of 62.3%.
- Pays a dividend yield of 6.1%.
- Company is almost debt-free.
- Revenue grew 650358208% YoY.
- Stock trades at a high P/E of 120.
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹284 Cr | ₹313 Cr | ₹310 Cr | ₹311 Cr | ₹339 Cr | ₹325 Cr | ₹374 Cr | ₹370 Cr |
| EBITDA | ₹43 Cr | ₹112 Cr | ₹122 Cr | ₹79 Cr | ₹89 Cr | ₹119 Cr | ₹109 Cr | ₹133 Cr |
| Net Profit | ₹17 Cr | ₹82 Cr | ₹91 Cr | ₹61 Cr | ₹66 Cr | ₹89 Cr | ₹78 Cr | ₹95 Cr |
| EPS | — | — | — | — | — | — | — | — |
| Metric | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹927 Cr | ₹1,425 Cr | ₹1,027 Cr | ₹1,128 Cr | ₹1,248 Cr | ₹1,167 Cr | ₹945 Cr | ₹1,408 Cr |
| EBITDA | ₹0 Cr | ₹355 Cr | ₹234 Cr | ₹254 Cr | ₹315 Cr | ₹294 Cr | ₹312 Cr | ₹0 Cr |
| Net Profit | ₹0 Cr | ₹254 Cr | ₹177 Cr | ₹193 Cr | ₹229 Cr | ₹201 Cr | ₹234 Cr | ₹327 Cr |
| EPS | — | 153 | 107 | 116 | 138 | 121 | 141 | — |
| Metric | Dec 2018 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹1,759 Cr | ₹1,176 Cr | ₹986 Cr | ₹888 Cr | ₹1,101 Cr | ₹794 Cr | ₹794 Cr | ₹841 Cr |
| Total Liabilities | ₹219 Cr | ₹269 Cr | ₹282 Cr | ₹272 Cr | ₹350 Cr | ₹256 Cr | ₹257 Cr | ₹317 Cr |
| Equity | ₹1,540 Cr | ₹906 Cr | ₹704 Cr | ₹616 Cr | ₹751 Cr | ₹538 Cr | ₹537 Cr | ₹525 Cr |
| Total Debt | — | — | — | — | — | — | — | ₹9 Cr |
| Metric | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | ₹337 Cr | ₹315 Cr | ₹233 Cr | ₹326 Cr | ₹313 Cr | ₹250 Cr | ₹338 Cr |
| Investing | ₹165 Cr | ₹-32 Cr | ₹-26 Cr | ₹-21 Cr | ₹-7 Cr | ₹10 Cr | ₹1 Cr |
| Financing | ₹-883 Cr | ₹-387 Cr | ₹-289 Cr | ₹-98 Cr | ₹-418 Cr | ₹-235 Cr | ₹-344 Cr |
| Free Cash Flow | ₹337 Cr | ₹315 Cr | ₹233 Cr | ₹326 Cr | ₹313 Cr | ₹250 Cr | ₹322 Cr |
Healthcare · Drug Manufacturers - Specialty & Generic
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.
www.pghealthindia.com ↗As of 2026-06-30
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% | 51.8% |
| FIIs | 7.4% | 7.6% | 6.2% | 6.4% | 6.6% | 7% | 6.9% | 7% | 7.2% | 7% | 6.2% | 6.3% |
| DIIs | 12.1% | 12.7% | 13.7% | 14.6% | 14.8% | 14.7% | 14.2% | 14.2% | 13.9% | 13.8% | 13.7% | 12.4% |
| Public | 28.7% | 27.9% | 28.2% | 27.2% | 26.7% | 26.5% | 27.1% | 27% | 27% | 27.4% | 28.3% | 29.4% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 57,919 | 56,730 | 56,778 | 55,923 | 54,792 | 53,736 | 53,993 | 52,478 | 50,006 | 49,302 | 50,883 | 49,056 |
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
| Name | Category | Stake | Shares |
|---|---|---|---|
| Procter And Gamble Overseas India B.v. | Shareholding of Promoter and Promoter Group | 51.8% | 86,01,071 |
| Nippon Life India Trustee Ltd-a/c Nippon India Sma | Public Shareholding | 4.2% | 6,94,659 |
| Life Insurance Corporation Of India | Public Shareholding | 1.9% | 3,16,610 |
| Uti-mnc Fund | Public Shareholding | 1.7% | 2,79,830 |
| Aditya Birla Sun Life Trustee Private Limited A/c | Public Shareholding | 1.2% | 2,02,796 |
| Gillette India Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Gillette Diversified Operations Pvt. Ltd. | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Procter & Gamble Home Products Private Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Procter & Gamble Hygiene & Health Care Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Temple Trees Impex & Investment Private Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| 1837 Llc | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Agile Pursuits Franchising, Inc. | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Agile Pursuits, Inc. | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Arbora & Ausonia, S.l.u. | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Braun (shanghai) Co., Ltd. | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Braun Gmbh | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Celtic Insurance Company, Inc. | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Detergent Products Sarl | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Detergenti S.a. | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Farmacy Beauty, Llc | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Farmacy Limited | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Fater Central Europe Srl | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Fater Eastern Europe Llc | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Fater Portugal Unipessoal Lda | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Fater S.p.a. | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Gillette India Limited | 0 | 0% | 2026-06-30 |
| Gillette Diversified Operations Pvt. Ltd. | 0 | 0% | 2026-06-30 |
| Procter & Gamble Home Products Private Limited | 0 | 0% | 2026-06-30 |
| Procter & Gamble Hygiene & Health Care Limited | 0 | 0% | 2026-06-30 |
| Temple Trees Impex & Investment Private Limited | 0 | 0% | 2026-06-30 |
| Procter And Gamble Overseas India B.v. | 0 | 0% | 2026-06-30 |
| 1837 Llc | 0 | 0% | 2026-06-30 |
| Agile Pursuits Franchising, Inc. | 0 | 0% | 2026-06-30 |
| Agile Pursuits, Inc. | 0 | 0% | 2026-06-30 |
| Arbora & Ausonia, S.l.u. | 0 | 0% | 2026-06-30 |
| Braun (shanghai) Co., Ltd. | 0 | 0% | 2026-06-30 |
| Braun Gmbh | 0 | 0% | 2026-06-30 |
| Name | Designation | Year |
|---|---|---|
| Milind Thatte | Managing Director | 2025 |
| Aalok Agrawal | Non Executive Director | 2025 |
| S Madhavan | Chairperson | 2025 |
| Seema Sambasivan | Non Executive Director | 2025 |
| Krishna Sarma | Independent Director | 2025 |
| SHARAD TYAGI | Independent Director | 2025 |
| Zeal Rupani | Company Sec. & Compli. Officer | 2025 |
| Shashank Srowthy | Additional Director & CFO | 2025 |
| Segment | Revenue | Share |
|---|---|---|
| Pharmaceuticals | ₹766 Cr | 76.9% |
| Chemicals | ₹231 Cr | 23.1% |
| Region | Revenue | Share |
|---|---|---|
| Domestic | ₹871 Cr | 93.2% |
| Export | ₹64 Cr | 6.8% |
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹10 | 18 | 17 | 17 |
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-08-06 | Board Meetings | — |
| dividend | 2026-02-12 | ₹110 (1100%) | Interim |
| dividend | 2026-02-12 | ₹50 (500%) | Special |
| dividend | 2025-08-22 | ₹45 (450%) | Final |
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 100 | 0 | 0 | 6 | 16 | 280 |
| 2025 | 1 | 0 | 0 | 0 | 0 | 1 |
| 2025 | 27 | 0 | 0 | 0 | 0 | 47 |
📍 Godrej One 8th Floor, Projshanagar Vikhroli (East), Mumbai, Maharashtra, 400079
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search